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Background: The relationship between diabetes mellitus (DM) and periodontal disease is bidirectional. DM is a
predisposing and modifying factor of periodontitis, which, in turn, worsens glycemic control and increases proteins
found in the acute phase of inflammation, such as C-reactive protein. The gold standard for the treatment of
periodontal disease is oral hygiene orientation, scaling and planing. Moreover, systemic antibiotic therapy may be
employed in some cases. In an effort to minimize the prescription of antibiotics, photodynamic therapy (PDT) has
been studied as an antimicrobial technique and has demonstrated promising results. The aim of the proposed
study is to determine whether PDT as a complement to periodontal therapy (PT) is helpful in the metabolic control
of individuals with type 2 diabetes and the reduction of acute-phase inflammatory markers.
Methods/Design: The patients will be randomized using a proper software program into two groups: 1) PT +
placebo PDT or 2) PT + active PDT. All patients will first be examined by a specialist, followed by PT performed by two
other healthcare professionals. At the end of each session, PDT (active or placebo) will be administered by a
fourth healthcare professional. The following will be the PDT parameters: diode laser (660 nm); power output =
110 mW; exposure time = 90 s per point (9 J/point); and energy density = 22 J/cm2. The photosensitizer will be
methylene blue (50 μg/mL). The patients will be re-evaluated 15, 30, 90 and 180 days after treatment. Serological ex-
aminations with complete blood count, fasting glucose, glycated hemoglobin and salivary examinations to screen
for tumor necrosis factor alpha, interleukin 1, interleukin 6, ostelocalcin, and osteoprotegerin/RANKL will be performed
at each evaluation. The data will be statistically evaluated using the most appropriate tests.
Discussion: The results of this study will determine the efficacy of photodynamic therapy as an adjuvant to
periodontal treatment in diabetic patients.
Trial registration: The protocol for this trial was registered with Clinical Trials registration number NCT01964833 on
14 October 2013.
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The term ‘diabetes mellitus’ (DM) describes a metabolic
disorder with a multifactor etiology characterized by
chronic hyperglycemia, with alterations in the metabol-
ism of carbohydrates, lipids and proteins due to deficient
insulin secretion and/or insulin action [1]. DM is a
major public health problem worldwide, with a preva-
lence rate of 246 million individuals, which is expected
to reach 366 million by the year 2030 [1]. Moreover, the
World Health Organization (WHO) projects a twofold
increase in deaths related to diabetes between 2005 and
2030. In Brazil, approximately 10 million individuals
have diabetes [2]. The aim of treatment for type 2 dia-
betes mellitus (T2DM) is to balance glycemic, metabolic
and cardiovascular control to prevent the development
of diabetes symptoms and avoid complications. This re-
quires a coordinated multidisciplinary approach centered
on the patient [1].
Periodontal disease is considered the sixth most com-
mon complication in individuals with diabetes [1]. Peri-
odontitis is an infectious disease characterized by the
destruction of the dental support structures, which leads
to attachment loss, bone resorption and consequent
tooth loss [3–6]. The relationship between DM and peri-
odontal disease is bidirectional. Severe periodontitis gen-
erally coexists with diabetes and inadequate glycemic
control can contribute to as much as a 2.8-fold greater
risk of developing periodontal disease. Moreover, peri-
odontal therapy (PT) reduces both systemic inflamma-
tion and resistance to insulin [7–9].
Periodontal disease is an oral infection caused by mi-
croorganisms and has been under extensive investigation
regarding its microbial content. In fact, it is caused by a
complex bacterial biofilm attached to the tooth and the
ability of the periodontopathogens to colonize the sub-
gingival sites is an important virulence factor. The main
objective of PT is to control bacterial infection and, con-
sequently, it is to help bone loss progression and exces-
sive inflammatory response as well. Thus, PT is focused
on scaling and root planing associated with patient oral
hygiene homecare [10].
The destruction of the periodontium is triggered in re-
sponse to the microbial challenge to the biofilm (dental
plaque) accumulated on the tooth surface. More than
108 bacteria and 150 different species can be found in
1 mm3 of biofilm weighing 1 mg. Eleven of these species
are associated with periodontitis [11, 12]. Dental plaque,
especially Porphyromonas gingivalis, activates the im-
mune system through Toll-like receptors, which are re-
sponsible for the recognition of pathogens and the
regulation of both inflammation and bone metabolism.
These receptors and cytokines related to bone resorption
(interleukin (IL)-1, IL-6, and osteoprotegerin (OPG)/re-
ceptor activator of nuclear factor kappa-B ligand(RANKL)) are altered in individuals with diabetes and
have a direct association with bone loss [13].
Randomized clinical trials have shown that nonsurgical
PT (oral hygiene counseling, scaling, polishing and root
planing) leads to a significant reduction in plasma levels
of acute-phase proteins, such as C-reactive protein and
fibrinogen [14, 15]. The best results in studies that asso-
ciate systemic markers of diabetes and inflammation
with PT are found when some type of antimicrobial ther-
apy, especially doxycycline, is employed. However, the
American Academy of Periodontology (AAP) recom-
mends caution in the use of antibiotics for PT due to
the side effects, the risk of favoring resistant microor-
ganisms and difficulty in completely reaching the dental
biofilm, which further favors the selection of microor-
ganisms [5]. Antimicrobial therapy is a field of investiga-
tion that faces constant challenges due mainly to the
increase in risk factors related to infection. The develop-
ment of resistance to antimicrobial agents in pathogenic
microorganisms is an evolutional process initiated by ex-
posure to these drugs, which makes this issue all the
more challenging. The indiscriminant use of antibiotics
in recent decades has accelerated the natural selection of
resistant microbial strains by allowing the rapid evolu-
tion of the genetic recombination of resistance and mu-
tation factors [16–18]. In Brazil, the National Health
Surveillance Agency (ANVISA) has adopted a number
of measures aimed at monitoring microbial resistance in
healthcare services and preventing the situation from be-
coming worse. Such actions have the direct participation
of the Pan American Health Organization (PAHO),
which held a conference with a number of countries in
2005 to discuss and define strategies aimed at combating
microbial resistance [18].
Besides efforts at minimizing the consequences of
this phenomenon, it is essential to find alternative
forms of treatment that are both effective and access-
ible. In this context, photodynamic therapy (PDT) has
emerged as a possibility for the treatment of different
diseases of significant clinical importance [19–23]. This
therapeutic resource is employed to cause cell death
based on the use of substances with photosensitizing
properties and the administration of light at an appro-
priate wavelength. The photodynamic process leads to
the formation of free radicals and singlet oxygen, which
have cytotoxic effects that can lead to the death of mi-
croorganisms [24]. PDT has demonstrated antimicro-
bial action in organized biofilms, especially against
Porphyromonas gingivalis [22, 25, 26].
The objectives of this work are: a) to assess the effi-
cacy of PDT as an antimicrobial complement to PT in
individuals with T2DM; b) investigate whether PT asso-
ciated with PDT affects glycemic control; c) investigate
whether PDT in combination with PT has a local effect
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RANKL in the crevicular fluid.
Methods/Design
A randomized, parallel, double-blind, clinical trial will
be conducted involving 26 patients recruited from the
periodontal clinics of the Nove de Julho University
(UNINOVE) (Brazil), who will be randomly allocated to
two groups. The project for the study was approved by
the Human Research Ethics Committee of the university
(Number 375,454) on 14 August 2014 and it is identified
in ClinicalTrials.gov as NCT01964833. Patients who meet
the eligibility criteria and who agree to participate will sign
a statement of informed consent approved by the Research
Ethics Committee of the university.
Inclusion criteria
The inclusion criteria comprise T2DM patients aged
18 years or older with adequate glycemic control [1, 2, 18];
chronic periodontitis [5]; presence of at least 15 teeth and
at least four teeth with bleeding upon probing and a
probing depth greater than 4 mm [27, 28]; and under
follow-up with an endocrinologist.
Exclusion criteria
The exclusion criteria comprise current smokers or
regular smoking 12 months prior to enrollment; pa-
tients with anemia; active cancer; history of antibiotic
therapy in the previous six months; history of anti-
inflammatory therapy in the previous three months;
clotting disorder (use of anticoagulant, presence of liver
disease, thrombocytopenia and immunosuppression);
those currently pregnant; and those currently undergoing
orthodontic treatment.
Experimental groups and study design
The sample size was calculated based on previous stud-
ies in the literature using data related to differences in
mean and standard deviation values [29], determining a
minimum of 13 patients with T2DM required to detect
significant differences in clinical variables between evalu-
ation times. Thirteen patients will be randomly allocated
to each experimental group: Group 1 - PT (oral hygiene
counseling, root scraping and planing and tooth polishing)
[5] + placebo PDT; Group 2 - PT + active PDT. Evalua-
tions will be performed at baseline as well as 15, 30, 90
and 180 days after the completion of treatment. Fig. 1
displays the flowchart of the study.
Randomization of patients and allocation concealment
Randomization of the patients to the different groups
will be performed with the appropriate software pro-
gram. Only the lead researcher will have access to the
randomization list. Allocation to the two groups will becarried out in blocks of five at a proportion of 1:1. Each
patient will receive a sealed envelope to deliver to the
operator in charge of the PDT.
The patients will be sent to Operator A for the peri-
odontal examination. Without knowledge of the results
of this examination, the patients will be treated by Op-
erators B and C for PT, which will involve oral hygiene
instructions as well as supragingival and subgingival
scaling and planing in up to four sessions. At the end
of each session, the patients will be sent to Operator
D, who will administer either placebo or active PDT
based on the content of the sealed envelope. Thus,
both the patients and operator in charge of the peri-
odontal examinations will be blinded to the PDT
protocol (a double-blind study).
Examinations for glycemic control and blood count
Fasting blood sugar and glycated hemoglobin examina-
tions will be performed at baseline as well as 90 and
180 days after the completion of treatment. All examina-
tions will be carried out at the same laboratory affiliated
with the university.
Clinical periodontal examination, periodontal treatment
and photodynamic therapy
The clinical periodontal examinations will be performed
by a single examiner specialized in periodontics, who
will evaluate six regions of each tooth with a 15-mm
probe (North Carolina model, Hu-Friedy, Chicago, IL,
USA). The following aspects will be recorded: plaque
index, bleeding upon probing, probing depth, gingival
recession and attachment loss [4, 6]. Evaluations will be
carried out at baseline (prior to initial treatment) as
well as 15, 30, 90 and 180 days after the completion of
treatment.
PT will consist of oral hygiene instructions, with the
monitored orientation of brushing technique and recom-
mendation of the daily use of dental floss. Calculus de-
posits will also be removed using ultrasound equipment
with the appropriate tips for periodontics as well as scal-
ing and planing with dental instruments, as recom-
mended by the AAP [5]. Treatment will be carried out
in two to four one-hour sessions with the use of local
anesthesia (typically mepivacaine 2 % with 1:100,000
norepinephrine). Gracey periodontal curettes (number
3/4, 5/6, 7/8, 11/12 and 13/14, Hu-Friedy, Chicago, IL,
USA) will be used for the removal of the dental calculus.
Other biofilm retention factors, such as caries, condemned
teeth and poorly fitted restorations, will be removed
during the sessions of PT.
PDT will be administered at the end of the PT session
at sites with pocket depths equal to or greater than
4 mm. A diode laser (Photon laser III, DMC, São Carlos,
Brazil) will be used at the 660 nm wavelength, with an
Fig. 1 Flow chart of study design
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point (9 J/point). Each irradiation point will have ap-
proximately 0.4 cm2, with an energy density per point
of 22 J/cm2 and power density of 250 mW/cm2. The
photosensitizer (Chimiolux 0.005 %, DMC, São Carlos,
Brazil) will be used, the active ingredient of which is
methylene blue at a concentration of 50 μg/mL, corre-
sponding to 160 μM. The photosensitizer will be depositedin each periodontal pocket using a syringe, with appli-
cation from the fundus of the pocket in the coronal
direction. Two minutes will be respected prior to
irradiation to allow the medication time to stain all
the microbial biofilm. The laser will be applied to the
mucosa over the oral epithelium using an optical fiber.
Following irradiation, excess medication will be re-
moved with a jet of water.
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OPG/RANKL in the crevicular fluid of the periodontal
pocket
Crevicular fluid will be collected from the previously de-
fined sites with a probing depth equal to or greater than
4 mm that will receive treatment. Collection will be per-
formed with relative isolation using cotton rolls following
the removal of the supragingival plaque with periodontal
curettes and air drying for five seconds. Absorbent paper
strips (PerioPaper, ProFlow Inc., Amityville, NY, USA) will
be individually inserted into each site for 30 s [30]. The
collections will be performed by a single researcher. The
volume of crevicular fluid samples will be measured using
the Periotron 8000 micro-moisture meter (Oraflow
Inc., Smithtown, NY, USA). The samples will then be
placed in duly identified sterile plastic microtubes, tem-
porarily stored in dry ice and subsequently stored in a
freezer at −80 °C.
Primary and secondary outcome
The primary outcome variable of the study was clinical
attachment level. Secondary outcome variables were
probing pocket depth, bleeding on probing, plaque index
and level of IL-1, IL-6, tumor necrosis factor (TNF)-
alpha, osteocalcin and OPG/RANKL.
Data analysis
The data will be submitted to the appropriate statistical
tests for the determination of differences between the
groups. Frequency distributions will be determined. The
unpaired parametric t test for two samples will be used
for data that demonstrate normal distribution, with the
level of significance set at 95 % (P <0.05). Data with a
log-normal curve will be normalized by the replacement
of measures with the base-10 logarithm of their values.
In both cases, graphs will be created based on the mean
and standard deviation of the data. Data that do not
have normal or log-normal distribution will be analyzed
using the nonparametric Mann–Whitney test, with the
level of significance set to 95 % (P <0.05). These data will
be presented in box plots and quartiles constructed
based on the median values. All analyses will be performed
using the Origin Pro 8™ software program (OriginLab,
Northampton, MA, USA).
Trial status
Patient recruitment is not completed.
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